Back to search results
NCT06919640

Psilocybin With Intracranial Neural Sensing

Enrolling by Invitation
PHASE1Ages 21–75Interventional
Joshua Woolley, MD, PhD
~20 participants
Updated 2025-06-06 on ClinicalTrials.gov
What's tested:Psilocybin

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Changes in neural functional connectivity
Measured over Drug administration to 90 days following

Conditions

Chronic Pain

Explore related trials

Chronic Pain

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Joshua Woolley, MD/PhD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco
  • Prasad Shirvalkar, MD/PhD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Currently implanted chronic brain sensing device (such as RC+S or Percept)
Not currently enrolled in another trial
Ability to speak and read English
Able to attend all in-person and virtual visits
No changes in medication or major surgical procedures anticipated for the trial
Able to identify someone to accompany from the research unit at the end of drug administration day or agreement to have a study team member accompany them from the research unit

Exclusion

A health condition that makes this study unsafe or unfeasible, determined by study physicians
Use of medication, vitamins, or supplements and unwilling or unable to discontinue medications that have problematic interactions with psilocybin
Adulthood epilepsy or other seizure disorder
Require supplemental oxygen
Medical finding or diagnosis that would make participation in this trial unsafe

What this trial measures

  • Changes in neural functional connectivityDrug administration to 90 days following

    Measured by high-gamma coherence, cross-correlations, and Granger Causality